Raloxifene and prevention of vertebral fracture (cont'd)

Prescrire International

Volumn 9, Issue 50, 2000, Pages 190-191

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PLACEBO; RALOXIFENE;

AGED; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; PRIMARY PREVENTION; REVIEW; RISK; SECONDARY PREVENTION; THROMBOEMBOLISM; VERTEBRA FRACTURE;

BREAST NEOPLASMS; CLINICAL TRIALS; DIABETES MELLITUS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; SPINAL FRACTURES; THROMBOEMBOLISM; UTERINE NEOPLASMS;

EID: 0034456820     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (5)

1. "The effect of 2 and 3 years of raloxifene on vertebral and non vertebral fractures in post menopausal women with osteoporosis"
2. "Raloxifène"
3. "Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post menopausal women. Two-year findings from the multiple outcomes of raloxifene evaluation (MORE) trial"
4. "Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-years randomized clinical trial"
5. " The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial"